We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00553865
First Posted: November 6, 2007
Last Update Posted: June 29, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jeil Pharmaceutical Co., Ltd.
  Purpose
The purpose of this study is to determine the optimal dosage of the clinical trial which is evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.

Condition Intervention Phase
Essential Hypertension Drug: OJP-2028 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A 8-Week, Randomized, Double-blind, Parallel Designed, Phase II Multi-center Clinical Trial to Evaluate the Antihypertensive Efficacy and the Safety of OJP-2028 Tablets in Patients With the Uncomplicated Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Jeil Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Average SiDBP Differences of test group vs control group per each dosage by comparison with the baseline. [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Average SiSBP Differences of each group by comparison with the baseline. [ Time Frame: 8 weeks ]
  • Responder rate of each group by comparison with the baseline. [ Time Frame: 8 weeks ]
  • Average SiDBP and SiSBP Differences of each group by comparison with the baseline. [ Time Frame: 8 weeks ]

Enrollment: 120
Study Start Date: November 2007
Study Completion Date: November 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
OJP-2028 1mg/day
Drug: OJP-2028
Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Experimental: Group 2
OJP-2028 2mg/day
Drug: OJP-2028
Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Experimental: Group 3
OJP-2028 4mg/day
Drug: OJP-2028
Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Placebo Comparator: Group 4
Placebo
Drug: OJP-2028
Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Group 5
Reference drug
Drug: OJP-2028
Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.

Detailed Description:
Evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult men and women (Age 18-75 years)
  2. Uncomplicated essential hypertension: Clinic sitting SiDBP between 90 and 109 mmHg after 2 week placebo run-in period

Exclusion Criteria:

  1. Secondary hypertension
  2. History and/or signs of cardiovascular complications (eg; myocardial infarction, unstable angina)
  3. Pregnancy or lactation
  4. Contraindications to the antihypertensive drugs to be used during the treatment period
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00553865


Locations
Korea, Republic of
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of
Sponsors and Collaborators
Jeil Pharmaceutical Co., Ltd.
Investigators
Principal Investigator: CHEOL HO KIM Seoul National University Bundang Hospital
  More Information

Responsible Party: Jeil Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT00553865     History of Changes
Other Study ID Numbers: OJP-2028-II
First Submitted: November 3, 2007
First Posted: November 6, 2007
Last Update Posted: June 29, 2016
Last Verified: September 2014
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents